Advertisement

International Journal of Clinical Pharmacy

, Volume 41, Issue 6, pp 1599–1610 | Cite as

Preventability analysis of adverse drug reactions in a Jordanian hospital: a prospective observational study

  • Lama Al Damen
  • Iman BashetiEmail author
Research Article

Abstract

Background Adverse drug reactions remain to be an issue that compromise patient’s safety in Jordan and worldwide. In Jordan, an assessment of factors involved in preventability of adverse drug reactions has not been conducted previously. Objectives To describe the proportion of preventable adverse drug reactions, and the causes of hospital-related preventable adverse reactions in one Jordanian hospital. Methods A prospective observational study of 4 months duration conducted by clinical pharmacists in the hospital. Setting Surgical and medical wards in one Jordanian private hospital. Main outcome measure Proportions of admissions related to adverse drug reactions, proportions of preventable reactions and analysis of the factors involved in the preventable adverse drug reactions. Results Out of 350 admissions recorded during the study period, a total of 38 (10.8%) adverse reactions were detected. Among those, 29 (8.3%) were detected in the hospital and 9 (2.6%) were the cause of the hospital admission. Many (44.7%) of the adverse drug reactions were preventable (31.6% were probably preventable and 13.1% were definitely preventable). About half (55.3%) were unpreventable. Insufficient monitoring was involved in 29.4% of the preventable adverse reactions and inappropriate dosing and drug–drug interactions were independently responsible for 17.6% of the preventable adverse reactions. Conclusion A high proportion of the identified adverse drug reactions were found to be preventable. Insufficient monitoring and inappropriate dosing were the most important factors associated with preventable adverse drug reactions. Nationally, more focused efforts need to be stimulated to prevent preventable adverse drug reactions in hospitals.

Keywords

Adverse drug reactions Hospital Jordan Preventability analysis 

Notes

Acknowledgements

The authors are grateful to the Applied Science Private University, Amman, Jordan, for their full support to conduct this research . The authors wish to thank also the clinical pharmacists working at the hospital who have helped in the clinical observation. Finally, the authors wish to thank Dr. Emad Al Dujaili for proof reading the article.

Funding

No specific funding was received to support this research.

Conflicts of interest

The authors declare no conflict of interests.

References

  1. 1.
    World Health Organization. Quality Assurance and Safety of Medicines Team. Safety of medicines: a guide to detecting and reporting adverse drug reactions: why health professionals need to take action; 2002. https://apps.who.int/iris/handle/10665/67378. Acessed 1 June 2018.
  2. 2.
    Rawlins M, Thomson J. Mechanisms of adverse drug reactions. In: Davies DM, editor. Textbook of adverse drug reactions. Oxford: Oxford University Press; 1991. p. 18–45.Google Scholar
  3. 3.
    Bouvy JC, De Bruin ML, Koopmanschap MA. Epidemiology of adverse drug reactions in Europe: a review of recent observational studies. Drug Saf. 2015;38:437–53.CrossRefGoogle Scholar
  4. 4.
    Alomar M. Factors affecting the development of adverse drug reactions (Review article). Saudi Pharm J. 2014;22:83–94.CrossRefGoogle Scholar
  5. 5.
    Maxwell S. Rational prescribing: the principles of drug selection. Clin Med (Lond). 2016;16:459–64.CrossRefGoogle Scholar
  6. 6.
    Bordet R, Gautier S, Le Louet H, Dupuis B, Caron J. Analysis of the direct cost of adverse drug reactions in hospitalised patients. Eur J Clin Pharmacol. 2001;56:935–41.CrossRefGoogle Scholar
  7. 7.
    http://www.jfda.jo. Accessed date Oct 2018.
  8. 8.
    Queneau P, Bannwarth B, Carpentier F, Guliana JM, Bouget J, Trombert B, et al. Emergency department visits caused by adverse drug events: results of a French survey. Drug Saf. 2007;30:81–8.CrossRefGoogle Scholar
  9. 9.
    Howard RL, Avery AJ, Howard PD, Partridge M. Investigation into the reasons for preventable drug related admissions to a medical admissions unit: observational study. Qual Saf Health Care. 2003;12:280–5.CrossRefGoogle Scholar
  10. 10.
    Olivier P, Boulbes O, Tubery M, Lauque D, Montastruc JL, Lapeyre-Mestre M. Assessing the feasibility of using an adverse drug reaction preventability scale in clinical practice. Drug Saf. 2002;25:1035–44.CrossRefGoogle Scholar
  11. 11.
    Zed PJ, Abu-Laban RB, Balen RM, Loewen PS, Hohl CM, Brubacher JR, et al. Incidence, severity and preventability of medication-related visits to the emergency department: a prospective study. CMAJ. 2008;178:1563–9.CrossRefGoogle Scholar
  12. 12.
    Winterstein AG, Hatton RC, Gonzales-Rothi R, Johns TE, Segal R. Identifying clinically significant preventable adverse drug events through a hospital’s database of adverse drug reactions reports. Am J Health Syst Pharm. 2002;59:1742–9.CrossRefGoogle Scholar
  13. 13.
    Forster AJ, Worthington JR, Hawken S, Bourke M, Rubens F, Shojania K, et al. Using prospective clinical surveillance to identify adverse events in hospital. BMJ Qual Saf. 2011;20:756–63.CrossRefGoogle Scholar
  14. 14.
    Smits M, Zegers M, Groenewegen PP, Timmermans DR, Zwaan L, van der Wal G, Wagner C. Exploring the causes of adverse events in hospitals and potential prevention strategies. Qual Saf Health Care. 2010;19(5):e5.PubMedGoogle Scholar
  15. 15.
    Alsbou M. Incidence of adverse drug reactions in Alkarak Governmental Hospital: a pilot study. J Med. 2010;44(4):444–6.Google Scholar
  16. 16.
    Alsbou M, Alzubiedi S, Alzobi H, Samhadanah NA, Alsaraireh Y, Alrawashdeh O, et al. Adverse drug reactions (ADRs) experience at Al-Karak Teaching Hospital in Jordan. Int J Clin Pharm. 2015;37:1188–93.CrossRefGoogle Scholar
  17. 17.
    Raut A, Patel PK, Patel CD, Pawar AK. Preventability, predictability and seriousness of adverse drug reactions amongst medicine inpatients in a teaching hospital: a prospective observational study. Int J Pharm Chem Sci. 2012;1:1293–9.Google Scholar
  18. 18.
    World Health Organization. Programme and projects: classifications. http://www.who.int/classifications/icd/en/index.htm. Accessed 1 June 2018.
  19. 19.
    World Heath Organization. ATC Index with DDDs 2003. Guidelines for ATC classification and DDD assignment; 2003.https://www.who.int/classifications/atcddd/en. Accessed 1 June 2018.
  20. 20.
    Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–45.CrossRefGoogle Scholar
  21. 21.
    Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting ADRs. Am J Hosp Pharm. 1992;49:2229–32.PubMedGoogle Scholar
  22. 22.
    Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm. 1992;27:538.PubMedGoogle Scholar
  23. 23.
    Moore N, Lecointre D, Noblet C, Mabille M. Frequency and cost of serious adverse drug reactions in a Department of General Medicine. Br J Clin Pharmacol. 1998;45:301–8.CrossRefGoogle Scholar
  24. 24.
    Alhamid A, Zoe Aslanpour Z, Aljadhey H, Ghaleb M. Hospitalisation resulting from medicine-related problems in adult patients with cardiovascular diseases and diabetes in the United Kingdom and Saudi Arabia. Int J Environ Res Public Health. 2016;13:479.CrossRefGoogle Scholar
  25. 25.
    Aljadhey H, Mahmoud MA, Ahmed Y, Sultana R, Zouein S, Alshanawani S, et al. Incidence of adverse drug events in public and private hospitals in Riyadh, Saudi Arabia: the (ADESA) prospective cohort study. BMJ Open. 2016;6(7):e010831.CrossRefGoogle Scholar
  26. 26.
    Aljadhey H, Mahmoud MA, Mayet A, Alshaikh M, Ahmed Y, Murray MD, et al. Incidence of adverse drug events in an academic hospital: a prospective cohort study. Int J Qual Health Care. 2013;25:648–55.CrossRefGoogle Scholar
  27. 27.
    Farcas A, Bucsa C, Sinpetrean A, Leucuta D, Mogosan C, Dumitrascu D, et al. Preventability analysis of adverse drug reactions detected in two internal medicine departments in Romania. Intern Emerg Med. 2014;9:187–93.CrossRefGoogle Scholar
  28. 28.
    Dequito AB, Mol PG, van Doormaal JE, Zaal RJ, van den Bemt PM, Haaijer-Ruskamp FM, et al. Preventable and non-preventable adverse drug events in hospitalized patients: a prospective chart review in the Netherlands. Drug Saf. 2011;34:1089–100.CrossRefGoogle Scholar
  29. 29.
    Bates DW, Cullen DJ, Laird N. Incidence of adverse drug events and potential adverse drug events: implications for prevention. J Am Med Assoc. 1995;274(1):29–34.CrossRefGoogle Scholar
  30. 30.
    Kanjanarat P, Winterstein AG, Johns TE, Hatton RC, Gonzalez-Rothi R. Nature of preventable adverse drug events in hospitals: a literature review. Am J Health Syst Pharm. 2003;60:1750–9.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Faculty of PharmacyPetra UniveristyAmmanJordan
  2. 2.Department of Clinical Pharmacy and Therapeutics, Faculty of PharmacyApplied Science Private UniversityAmmanJordan

Personalised recommendations